- Home
- FATE vs COYA Comparison
FATE vs COYA Comparison
Compare FATE & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FATE | COYA |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 124.8M |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FATE | COYA |
|---|---|---|
| Price | $2.88 | $4.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.10 | ★ $15.80 |
| AVG Volume (30 Days) | ★ 4.9M | 262.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,646,000.00 | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $763.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $0.91 | $3.71 |
| 52 Week High | $3.23 | $7.75 |
Technical Indicators
Market Signals| Indicator | FATE | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 36.46 |
| Support Level | $1.01 | $3.98 |
| Resistance Level | $2.88 | $5.18 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 68.40 | 1.98 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.